Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004388 · ClinicalTrials.gov registry record · Phase 3
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
A Phase 3 study of Migraine and Headache, sponsored by Click Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT06004388 is a Phase 3 study of Migraine and Headache that has completed, run by Click Therapeutics. The registered enrollment target is 110 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06004388, a Phase 3 study of Migraine and Headache, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
Conditions Studied
Interventions
- DEVICE Click Digital Therapeutic
Study Locations (1)
New York
- Click Therapeutics - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2024-06-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06004388
The ClinicalTrials.gov registry entry for NCT06004388 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (69% lower). The listed sponsor is Click Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Click Digital Therapeutic is the first listed.
NCT06004388 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06004388 about?
NCT06004388 is a clinical study titled "Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)". Randomized study of two digital therapeutics for the prevention of episodic migraine in patients currently receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy
What is the current status of trial NCT06004388?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2023-07-21. Estimated completion is 2024-06-05.
What conditions does trial NCT06004388 study?
This clinical trial studies the following conditions: Migraine, Headache, Episodic Migraine, Headache, Migraine.
What interventions are being tested in trial NCT06004388?
The interventions under investigation include: Click Digital Therapeutic (DEVICE).
Who is sponsoring clinical trial NCT06004388?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004388 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
RECRUITING · Phase 3
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
RECRUITING · Phase 3
-
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RECRUITING · Phase 3
-
Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
RECRUITING · Phase 3
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.